CY1115744T1 - Παραγωγο σπειροϊμιδαζολονης - Google Patents

Παραγωγο σπειροϊμιδαζολονης

Info

Publication number
CY1115744T1
CY1115744T1 CY20141100870T CY141100870T CY1115744T1 CY 1115744 T1 CY1115744 T1 CY 1115744T1 CY 20141100870 T CY20141100870 T CY 20141100870T CY 141100870 T CY141100870 T CY 141100870T CY 1115744 T1 CY1115744 T1 CY 1115744T1
Authority
CY
Cyprus
Prior art keywords
spirimimazolone
product
acceptable salt
following formula
compound represented
Prior art date
Application number
CY20141100870T
Other languages
English (en)
Inventor
Toru Esaki
Yoshikazu Nishimura
Yoshiaki Isshiki
Naoki Okamoto
Yoshiyuki Furuta
Akemi Mizutani
Masateru Ohta
Wayne Wen Lai
Tomoya Kotake
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of CY1115744T1 publication Critical patent/CY1115744T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μία ένωση που αντιπροσωπεύεται με τον παρακάτων τύπο (1): όπου W, X, Y, R1, R2, R33, R34, m και n είναι όπως ορίζεται στις αξιώσεις ή φαρμακολογικώς αποδεκτό άλας αυτής.
CY20141100870T 2009-04-28 2014-10-23 Παραγωγο σπειροϊμιδαζολονης CY1115744T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009109256 2009-04-28
EP10769728.6A EP2433940B9 (en) 2009-04-28 2010-04-27 Spiroimidazolone derivative

Publications (1)

Publication Number Publication Date
CY1115744T1 true CY1115744T1 (el) 2017-01-25

Family

ID=43032174

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100870T CY1115744T1 (el) 2009-04-28 2014-10-23 Παραγωγο σπειροϊμιδαζολονης

Country Status (12)

Country Link
US (2) US9169254B2 (el)
EP (1) EP2433940B9 (el)
JP (1) JP5671453B2 (el)
CY (1) CY1115744T1 (el)
DK (1) DK2433940T3 (el)
ES (1) ES2525353T3 (el)
HR (1) HRP20141126T1 (el)
PL (1) PL2433940T3 (el)
PT (1) PT2433940E (el)
SI (1) SI2433940T1 (el)
TW (1) TWI496782B (el)
WO (1) WO2010126030A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5671453B2 (ja) * 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
EP2621901B1 (en) * 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
RS57190B1 (sr) 2012-12-10 2018-07-31 Chugai Pharmaceutical Co Ltd Derivat hidantoina
TWI686392B (zh) * 2014-06-09 2020-03-01 日商中外製藥股份有限公司 含有乙內醯脲衍生物之醫藥組合物
WO2015189901A1 (ja) 2014-06-09 2015-12-17 中外製薬株式会社 ヒダントイン誘導体含有医薬組成物
JP6290138B2 (ja) * 2014-06-09 2018-03-07 中外製薬株式会社 ヒダントイン誘導体含有医薬組成物
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
CN105017252B (zh) * 2015-06-30 2017-04-12 河南师范大学 具有生物活性的1,3,8‑三氮杂螺[4,5]癸烷‑2‑胍‑4‑酮类化合物及其制备方法和应用
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
EP3532459B1 (en) 2016-10-26 2023-08-02 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and medical uses thereof
RU2747400C2 (ru) * 2016-11-14 2021-05-04 Байондис Б.В. СПОСОБ ПОЛУЧЕНИЯ МОНОЗАЩИЩЕННЫХ α,ω-ДИАМИНОАЛКАНОВ
IT201600130729A1 (it) * 2016-12-23 2018-06-23 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione degli intermedi del delmopinolo
CN108003037B (zh) * 2018-01-18 2020-07-24 上海仁实医药科技有限公司 一种n-甲基-5-己烯-1-胺的合成工艺
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
MX2021001063A (es) 2018-07-30 2021-04-12 Chugai Pharmaceutical Co Ltd Dispersion solida de derivado de hidantoina.
WO2022081514A1 (en) * 2020-10-12 2022-04-21 The Regents Of The University Of Michigan Synthesis of egfr modulators
CN112142634A (zh) * 2020-11-02 2020-12-29 广州市科虎生物技术研究开发中心 一种（2-羧乙基）二甲基氯化锍的制备方法
CN112574226A (zh) * 2020-12-15 2021-03-30 海门华祥医药科技有限公司 5,6-亚甲基二氧基吲哚的制备方法
CN114409569A (zh) * 2021-12-23 2022-04-29 江苏长青农化股份有限公司 一种手性稻瘟酰胺的制备方法
EP4603546A1 (en) 2022-12-28 2025-08-20 Chugai Seiyaku Kabushiki Kaisha Solid dispersion containing substance to be dispersed, pharmaceutical composition containing same, and production methods therefor
CN116969831B (zh) * 2023-08-01 2025-09-23 菏泽皓元医药科技有限公司 一种莫奈太尔的中间体及其制备方法
CN117263810A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
WO2025226895A1 (en) * 2024-04-24 2025-10-30 Septerna, Inc. Agonists of parathyroid hormone 1 and incretin receptors comprising substituted or modified diaminomethylene pyrimidine-2,4,6-triones
WO2025226892A1 (en) * 2024-04-24 2025-10-30 Septerna, Inc. Spirocycle-containing diaminomethylene pyrimidine-2,4,6-trione agonists of parathyroid hormone 1 and incretin receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
CA2353924A1 (en) 1998-12-11 2000-06-22 F. Hoffmann-La Roche Ag Cyclic hydrazine derivatives as tnf-alpha inhibitors
AU2001284412A1 (en) 2000-08-30 2002-03-13 Teijin Limited Parathyroid hormone production inhibitors containing vitamin D3 derivatives
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US20070123548A1 (en) 2004-02-11 2007-05-31 Cowan David J Pth agonists
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
JP2008515895A (ja) * 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
WO2007135417A1 (en) * 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
EP2035420A2 (en) * 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
JP2010529069A (ja) * 2007-06-07 2010-08-26 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３アンタゴニストとしてのプロリンアミド誘導体
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (en) 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
JP5671453B2 (ja) 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
RS57190B1 (sr) 2012-12-10 2018-07-31 Chugai Pharmaceutical Co Ltd Derivat hidantoina

Also Published As

Publication number Publication date
SI2433940T1 (sl) 2015-01-30
PT2433940E (pt) 2014-12-12
US20120270838A1 (en) 2012-10-25
HRP20141126T1 (hr) 2015-01-30
PL2433940T3 (pl) 2015-03-31
JPWO2010126030A1 (ja) 2012-11-01
JP5671453B2 (ja) 2015-02-18
TWI496782B (zh) 2015-08-21
US9487517B2 (en) 2016-11-08
DK2433940T3 (en) 2015-01-12
TW201103938A (en) 2011-02-01
EP2433940B1 (en) 2014-09-24
WO2010126030A1 (ja) 2010-11-04
US9169254B2 (en) 2015-10-27
EP2433940A4 (en) 2012-10-10
ES2525353T3 (es) 2014-12-22
EP2433940A1 (en) 2012-03-28
EP2433940B9 (en) 2015-10-28
US20160016956A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
CY1115744T1 (el) Παραγωγο σπειροϊμιδαζολονης
CY1121854T1 (el) Αρυλoαζoλ-2-υλ κυανοαιθυλαμινο ενωσεις, μεθοδος κατασκευης και μεθοδος χρησης αυτων
CY1121792T1 (el) Ετεροκυκλικη ενωση
CY1123333T1 (el) Παραγωγα ινδολινονης και διαδικασια για την παραγωγη τους
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
CY1123705T1 (el) Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης
CY1118681T1 (el) Αναστολεις νεπριλυσινης
CY1119620T1 (el) Αναστολεις νεπριλυσινης
CY1120995T1 (el) Ετεροκυκλικη ενωση και χρηση αυτης
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
PA8809001A1 (es) Compuestos organicos
CY1118753T1 (el) Παραγωγα βενζοθειοφαινιου υποκατεστημενου με πιπεραζινη ως αντιψυχωσικοι παραγοντες
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
CR11454A (es) Derivados de isoxazolo-piridina
MX351513B (es) Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CY1119134T1 (el) Υποδοχεις της νεπριλυσινης
EA201070786A1 (ru) Бензофуропиримидиноны
CY1110489T1 (el) Παραγωγα ισοκινολινης
MA32877B1 (fr) Composes organiques
CY1114452T1 (el) Ενωσεις πυρρολιου
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
EA201070519A1 (ru) Соединения тропана
CY1114130T1 (el) Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης